Is Gabapentin a Controlled Substance in New York? State Laws and Prescription Rules
Meta description: Find out whether gabapentin is a controlled substance in New York, how prescription monitoring works, and what patients and prescribers should know.
Gabapentin is not classified as a controlled substance under New York or federal law. However, it is a prescription medication, and New York’s prescription-monitoring rules apply to its dispensing. That distinction matters: a drug can be monitored without being scheduled as a controlled substance. Here is how New York treats gabapentin, what the rules mean for patients and pharmacies, and how the medication’s safety and legal status compare across the United States.
Is Gabapentin a Controlled Substance in New York?
No. Gabapentin is not a Schedule II, III, IV, or V controlled substance in New York, and it is not federally scheduled under the Controlled Substances Act. It is nevertheless available only by prescription in the United States. A prescription requirement does not, by itself, make a medication a controlled substance.
New York’s controlled-substance schedules are established under state law and regulations. The federal government’s schedules are maintained under the Controlled Substances Act. Gabapentin is not listed as a controlled drug in those schedules. State laws can differ, however, so gabapentin’s classification in New York does not automatically apply in another state.
Gabapentin is the generic name for a medication sold under brand names that have included Neurontin and Gralise. It is an anticonvulsant medicine that is also prescribed for certain types of nerve pain. It is not an opioid, and it is not the same medication as pregabalin, sold as Lyrica. Pregabalin is a federally controlled Schedule V substance; gabapentin is not.
Why Does New York Monitor Gabapentin?
Not being controlled does not mean a medicine is exempt from oversight. New York requires pharmacies and other authorized dispensers to report specified prescription information to the state’s Prescription Monitoring Program (PMP). The PMP is a database used by authorized health professionals to review dispensing records and support safer prescribing.
New York added gabapentin to its PMP reporting requirements even though the medication is not scheduled as a controlled substance. This allows clinicians to consider a patient’s gabapentin prescription history alongside other relevant medication information. Reporting is an administrative and patient-safety measure; it does not turn gabapentin into a controlled substance or make it illegal to possess when prescribed.
New York State Department of Health materials describe the PMP and the reporting duties that apply to dispensers. Because rules and technical requirements can change, pharmacies and prescribers should check current state guidance rather than relying on older summaries.
Gabapentin Rules at a Glance
| Question | New York answer |
|---|---|
| Is gabapentin a controlled substance? | No. It is not scheduled under New York or federal controlled-substance law. |
| Can a person get it without a prescription? | No. Gabapentin is a prescription medication. |
| Is dispensing reported to New York’s PMP? | Yes. New York includes gabapentin in prescription-monitoring reporting requirements. |
| Is it an opioid? | No. Gabapentin is an anticonvulsant medication. |
| Is pregabalin treated the same way? | No. Pregabalin is federally Schedule V; gabapentin is not federally scheduled. |
What New York’s Prescription Monitoring Program Means
The PMP is a secure electronic database that collects information about prescriptions dispensed in New York for substances and medications covered by state reporting rules. Authorized practitioners and pharmacists may use it as part of medication review. It can help identify overlapping prescriptions, possible drug interactions, or patterns that warrant a conversation with the patient.
A PMP record is not a judgment about a patient. A prescription appearing in the database does not establish misuse, addiction, or wrongdoing. Clinicians interpret the information in context, including the reason for treatment, the patient’s medical history, and other medicines being used.
For patients, PMP reporting generally does not create a new application or registration step. The prescribing clinician writes the prescription, and the dispensing pharmacy follows applicable reporting requirements. Patients can ask their prescriber or pharmacist how their medication history is used and what information is recorded.
How Gabapentin Is Prescribed
In the United States, gabapentin is FDA-approved for certain seizure disorders and for postherpetic neuralgia, a type of nerve pain that can follow shingles. Clinicians also prescribe it for other conditions when they judge that the potential benefits outweigh the risks. Such use is called off-label prescribing and is a common, lawful part of medical practice.
The dose and schedule depend on the condition, response to treatment, kidney function, age, and other medicines. Gabapentin is cleared largely through the kidneys, so a prescriber may adjust the dose for someone with impaired kidney function. Patients should follow the instructions on their prescription rather than changing the dose on their own.
Because gabapentin is not a controlled substance, federal controlled-substance prescription rules—such as federal schedule-based limits on refills—do not apply to it in the same way they apply to scheduled drugs. Still, prescribers and pharmacies must follow applicable state prescribing, dispensing, and professional-practice requirements. The prescription’s directions and the clinician’s treatment plan remain important.
Safety Risks and Responsible Use
Gabapentin can cause sleepiness, dizziness, blurred vision, and problems with coordination. These effects can affect driving and other tasks requiring alertness, especially when treatment begins or the dose changes. Patients should learn how the medicine affects them before driving or operating machinery.
Combining gabapentin with opioids or other medicines that slow the central nervous system can increase sedation and may raise the risk of serious breathing problems. The U.S. Food and Drug Administration has warned about respiratory depression with gabapentinoids, especially for people who use opioid pain medicines or have certain breathing conditions, and for older adults. Patients should tell their prescriber and pharmacist about all prescription drugs, over-the-counter medicines, and supplements they use.
Gabapentin can also cause serious allergic reactions or mood-related changes in some people. Anyone experiencing trouble breathing, extreme difficulty waking, swelling of the face or throat, or another medical emergency should seek immediate help. New or worsening depression, unusual behavior, or thoughts of self-harm should be raised promptly with a health professional.
Patients should not stop gabapentin suddenly without medical guidance. Abrupt discontinuation may cause withdrawal symptoms and, in people taking it for seizure control, may increase the risk of seizures. A prescriber can advise whether a gradual dose reduction is appropriate.
Is Gabapentin Controlled in Other States?
Gabapentin’s classification varies by state. Some states have classified it as a controlled substance, while others require reporting to a prescription-monitoring program or impose additional rules without making it a controlled drug. Federal law does not schedule gabapentin, but a state’s stricter requirements can still apply within that state.
This distinction matters when someone travels, moves, or fills a prescription across state lines. A New York prescription may be subject to the destination state’s dispensing requirements. Pharmacies may also have policies for verifying prescriptions or handling transfers. Patients who are relocating or traveling for an extended period should contact their prescriber and pharmacy in advance.
For current information, patients can check with the state pharmacy board or health department where the prescription will be filled. A pharmacist can explain practical dispensing requirements, but questions about a person’s legal situation may require advice from a qualified attorney.
Common Questions About Gabapentin in New York
Does PMP reporting mean gabapentin is a controlled substance?
No. New York can require reporting for a medication without placing it on a controlled-substance schedule. Gabapentin’s inclusion in the PMP supports medication review; it does not change its legal classification.
Can someone possess gabapentin in New York?
A person may possess gabapentin when it has been prescribed to them and is used according to the prescription. Since it is a prescription-only medication, taking or sharing someone else’s prescription is not a safe substitute for getting medical care. Patients should keep medication in its original labeled container when practical and follow their clinician’s instructions.
Can a New York doctor prescribe gabapentin?
Yes. A qualified prescriber may prescribe gabapentin when it is appropriate for the patient’s medical needs. The prescriber should consider the treatment goal, other medications, relevant health conditions, and the risks of side effects or interactions.
Can the pharmacy refuse to fill a gabapentin prescription?
A pharmacist may need to verify a prescription or resolve a safety, legal, or administrative concern before dispensing it. A delay or refusal does not mean gabapentin has become a controlled substance. Patients can ask the pharmacy what needs to be resolved and contact the prescriber if a replacement prescription or clarification is needed.
Where to Verify Current New York Rules
For authoritative information, consult the New York State Department of Health Prescription Monitoring Program, the state’s Bureau of Narcotic Enforcement, and the federal Drug Enforcement Administration’s controlled-substance schedules. The FDA’s gabapentinoid safety communication provides additional information about breathing risks.
Bottom line: Gabapentin is a prescription medication, but it is not a controlled substance in New York or under federal law. New York’s PMP reporting requirement is a separate oversight measure. For individual treatment questions, patients should consult their prescriber or pharmacist; state rules should be checked directly when filling a prescription outside New York.